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Glucose 6 phosphate dehydrogenase
levels in babies delivered at the University
of Ilorin teaching hospital.
babies with normal enzyme levels
were significantly higher than in
male babies with normal enzyme
levels (5.72 2.45 U/gHb versus
4.99 2.3 U/gHb, p = 0.002).
Enzyme levels in babies with G6PD
deficiency was comparable in both
males and females (2.05 ± 0.60
u/gHb in females and 2.1 0.66
U/gHb in males, p = 0.66). The
prevalence of G6PD deficiency was
comparable among males and
females (p = 0.81 = 0.06, RR =
1 . 0 2 , C I = 0 . 9 0 < R R < 1 . 1 5 ,
OR=1.04).
There is a high
prevalence of G6PD deficiency in
babies delivered at the University of
Ilorin Teaching Hospital, and the
enzyme deficiency appears to occur
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deficiency, an X-linked recessive
disorder, is the most common
enzymopathy producing disease




G6PD levels in babies delivered at
the University of Ilorin Teaching
H o s p i t a l w i t h a v i e w t o
determining the prevalence of
G6PD deficiency.
Samples of cord blood
were collected at delivery, from
933 babies who met set criteria.
Blood was assayed for G6PD
levels using a quantitative in vitro
test (RANDOX©).
A total of 348 (37.3%) of
the 933 tested subjects had G6PD
deficiency with enzyme activity of
≤ 2.8U/gHb. Glucose 6 Phosphate






Glucose-6-phosphate dehydrogenase (G-6-PD) is an
enzyme in the hexose monophosphate shunt that
catalyses the oxidation of glucose-6-phoshate to 6-
phosphogluconate. This is the rate limiting step of
the pathway. Concomitantly, Nicotinamide Adenide
Dinucleotide Phosphate (NADP ) is reduced to
NADPH. The NADPH, a required co-factor in
many biosynthetic reactions, maintains glutathione
in its reduced form. Reduced glutathione acts as a
scavenger for free radicals, and thus helps reduce
oxidized haemoglobin to free haemoglobin;
otherwise oxidized haemoglobin will precipitate as
Heinze bodies. The message of haemolysis has NOT
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been sent by this presentation. While many other
body cells have other mechanisms of generating
NADPH, the red blood cells rely completely on G-6-
PD activity because it is the only source of NADPH
that protects the cell against oxidative stress.
Glucose-6-phosphate dehydrogenase (G-6-PD)
deficiency is the most common disease producing
enzymopathy in humans. It is inherited as an X
linked recessive disorder. It affects about 400 million
people worldwide. The highest prevalence rates
occur in persons of African, Asian, Mediterranean or
Semitic descent. Specific prevalence rates
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Data Analysis
Study Population
This was done using EPI-info version 6 software.
Association between categorical variables were
tested using Chi-square test. Relationship between a
continuous variable and dependent variable were
tested using the Student t test or ANOVA as
appropriate.
For all statistical analysis, p <0.05 was considered
significant.
The study was conducted over a 10 month period
during which 4591 babies were delivered at the
University of Ilorin Teaching Hospital. They
comprised 2525 males and 2066 females with a male
to female ratio of 1.1:1. The gestational age of the
babies ranged from 26 weeks to 44 weeks, with a
mean GAof 39 3.9 weeks. Birth weight ranged from
7005450g with a mean of 3892 ± 1148g. Atotal of 933
babies had samples for G6PD assay collected during
this study.
Table 1 shows the baseline characteristics of study
subjects. There were 903 (96.8%) singleton deliveries
and 15 (3.2%) sets of twins. Babies delivered at term
constituted 79.9% of the study population, while
preterm babies made up 20.1% of the study
population. The male to female ratio was 1.3:1.





Figures in brackets are percentages of 933
USA and 50% in the Middle East. In Nigeria, an
estimated 21% of the male population is said to have
G-6-PD deficiency. In neonates, the prevalence
among jaundiced babies range from 30.9% - 50%in
Nigeria.
G-6-PD deficiency causes a clinical spectrum of
illness which includes a purely asymptomatic state,
acute haemolytic episodes (from drugs , infections,
ingestion of fava beans, diabetes mellitus), chronic
haemolysis (hereditary non-spherocytic haemolytic
anaemia), and neonatal jaundice.
Few studies have been conducted, in this part of the
world in this part of the world, to determine the G6PD
status of the newborn prior to the onset of jaundice.
This study was aimed to determine the G6PD enzyme
level in newborn babies prior to the onset of jaundice,
and to relate these enzyme levels to the baby's
gender/sex.
This cross sectional prospective study was performed
at the maternity unit of the University of Ilorin
Teaching Hospital, which is located in the North
Central region of Nigeria. Ethical approval was
obtained from the institutions' Ethical Review
Committee of the institution. Average yearly
deliveries range from 4500 5000 babies, with
virtually all babies being of WestAfrican descent.
Alternately delivered newborn babies whose mothers
gave consent were recruited into the study. Exclusion
criteria included babies whose gestational age was
greater than 42 weeks, babies with severe birth
asphyxia, and those with congenital abnormalities.
Blood from the placental end of the cord was drawn
and G6PD levels were assayed using an
diagnostic kit manufactured by RANDOX
Laboratories Limited (Ardmore Diamond Road,
Crumlin, Co.Antrim, United Kingdom, BT 294 QY.
For G6PD assay, 2ml of blood drawn from the
placental end of the cord was collected into EDTA
containing bottles after delivery. Enzyme level was
assayed using a quantitative in vitro test
(RANDOX©). Its principle is based on reduction of
NADP+ by G6PD present in red blood cells. The
NADPH generated fluoresces under UV light at a
wave length of 340nm. Enzyme activity is determined
by the rate of absorbance change. Red blood cell























Male : Female 1.3:1
166
And 2.05 0.60 U/gHb in females, p = 0.66). (Table 4)
Glucose-6-Phosphate Dehydrogenase levels
in normal and deficient neonates according to sex
The overall prevalence of G6PD deficiency as shown
in the study was 37.3% in the neonatal population. In
other words, about four out of every 10 babies born at
the teaching hospital was G6PD deficient. The
method used in enzyme assay in this study was
quantitative enzyme assay, rather than qualitative
(fluorescent spot). The fluorescence spot test is based
on the visual evaluation of fluoresced reduced
NADPH when activated by ultraviolet light so that,
the sample is considered G6PD enzyme “deficient”
when they do not fluorescence, and “normal” when
they fluorescence. Studies have shown that false
negative results may occur, with the use of the
fluorescent spot test, in heterozygote females and in
h o m o z y g o t e m a l e s f o l l o w i n g a n a c u t e
haemolysis. In one study involving known
female heterozygotes, G6PD deficiency was
diagnosed in 53% of these females by the use of
enzyme assay, but in only 7.5% of these females with
the use of the fluorescence spot test. This (florescent
spot test) was the method used in enzyme assay in
studies done in Nigeria thus, the prevalence rate in this
study is at a variance with rates determined by other
workers viz, 20.5%, 20.6%, and 35.3%.
Additionally, the babies recruited into these studies
already had jaundice. Enzyme levels assayed









Table 2 shows the distribution according to mean birth
weight and gestational age. The gestational age (GA)
of the babies studied ranged from 26 to 42 weeks with
a mean GA of 38 2.7 weeks. Birth weights ranged
from 800 - 5050g, with a mean of 2866.9 ± 710g
grammes.
Mean birth weight in relation to gestational
age
Glucose-6-Phosphate Dehydrogenase levels that
were ≥2.9U/gHb were regarded as normal, while
values ≤2.8U/gHb were regarded as deficient.
Stratification of G6PD levels into various ranges
Relative proportion of G6PD values
Three hundred and forty-eight babies (37.3% of 933)
were found to be G6PD deficient, thereby giving a
hospital based prevalence of 37.3%. They comprised
194 males (37.7% of male population) males and 154
females (36.8% of female population) females (p =
0.81 = 0.06 RR = 1.02, CI=0.90<RR<1.15,
OR=1.04).
The overall mean G6PD value was 4.1 2.48 U/gHb
(range 0.87 13.0 U/gHb). Among those with normal
G6PD values, males had a mean G6PD value of 4.99
2.3 U/gHb and females 5.7 2.45 U/gHb. Thus,
normal females had a mean G6PD value that was
significantly higher than that of normal males (p =
0.002).
Enzyme levels in babies with G6PD deficiency was



















26 – 29 18 (1.9) 1107.5 + 370
30 – 33 68 (7.3) 1565.2 + 252
34 – 36 101 (10.8) 2282.4 + 476
37 – 40 653 (69.9) 3099.7 + 509
41 – 42 93 (10) 3217.3 ± 626
Total 933 2866.9 ± 710
G6PD values (U/gHb) Number (t=933)
= 1 26 (2.8%)
2 86 (9.2%)
2 -2.8 236 (25.3%)
2.9 - 7.2 457 (49%)



































homozygous. Because of random X chromosome
inactivation by Lyonization the heterozygote female
has two red cell populations: one G6PD deficient, and
the other G6PD normal. In most instances, the
heterozygote female still has normal enzyme activity
but, the total G6PD activity of the heterozygote
female can range from near normal to near
deficient. It has also been postulated that in
geographic areas where G6PD deficiency is very
common, female newborns might be homozygous for
the trait, thus behaving like the hemizygous G6PD
deficient male newborn. A DNA analysis, which
would have served as a tie-breaker, was beyond the
financial scope of this study.
Overall, enzyme levels in normal females were
clearly higher than the levels in normal males. This
finding can, however, not be explained. The gene for
the G6PD enzyme is located on the X chromosome
and so, because the female is doubly endowed, she
should demonstrate higher enzyme levels. However,
because of the influence of Lyonization enzyme
levels in the female should not be appreciably higher
than in males. This will serve as grounds for further
research.
In view of the high prevalence of G6PD deficiency in
this region, newborn screening programmes should
be instituted to aid in the early diagnosis and
preemptive care of babies with this condition.
The major limitations of this study were our inability
to carry out DNA analysis on the sample drawn from
female neonates (financial and technological
constraints), and the low number of early preterm
neonates recruited.
Our thanks go to the nursing staff of the labour ward
UITH. We are also grateful to Dr. Olanrewaju of the
Department of Haematology and Mr. Akinyinka of
the Department of Chemical Pathology for their help







demonstrate enzyme activity in reticulocytes and
neocytes. In the enzyme variant responsible for
deficiency in the West African sub-region, GdA ,
enzyme activity wanes as the cells age so that
neocytes have near normal enzyme activity. Thus,
earlier studies conducted in this region would have
underestimated the level of enzyme deficiency in
neonates.
Studies, in this environment, where G6PD enzyme
was assayed prior to the onset of jaundice are few, and
hence a relative dearth of information on either the
incidence or prevalence rate of the enzyme
deficiency. In one study where enzyme activity was
assayed from cord blood samples, the prevalence
rate of G6PD deficiency did not appear to be the aim
of the researchers. Other studies in which G6PD
enzyme assays were determined at birth reveal
prevalence rates of 12.8% in the African-American
population in the US, 7.6% in Malaysia, and 3.2%
in Iran. The link between G6PD deficiency and
malaria is well documented, and with malaria
being holoendemic in Nigeria a higher prevalence of
the enzyme deficiency is to be expected. Luzzatto
in his work discovered that 22% of Nigerian adult
males, and 3 - 4% of female homzygotes were G6PD
deficient.
A similar proportion of females and males, in this
study, were found to be enzyme deficient ( = 0.06, p
= 0.81, RR = 1.02, CI=0.90<RR<1.15, OR=1.04). In
another study done on neonates with jaundice, using a
quantitative assessment of enzyme activity, 58% of
females and 50.3% of males in the study population
were found to be G6PD deficient. The cut off for
enzyme deficiency used in that study were levels that
were 40% of normal adult values (8.83 ±
1.59eU/gHb). This finding is contrary to what would
be expected of an X-linked disorder. It would
naturally be expected that the enzyme deficiency
would occur more in males because they carry only
one X chromosome. The females are however in the
unique position to have 3 genotypes: normal
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